Skip to main content
. Author manuscript; available in PMC: 2007 Jun 25.
Published in final edited form as: J Biotechnol. 2006 Jan 18;124(1):242–257. doi: 10.1016/j.jbiotec.2005.12.001

Figure 2.

Figure 2

Examples of structure modification of natural products to improve utility as clinical drugs. (A) Modification of rifamycin B to rifampicin to improve pharmacokinetic properties, (B) modification of geldanamycin to 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin to reduce human toxicity and (C) modification of taxol to taxotere to generate a proprietary molecule.